Relypsa (RLYP) Has Multiple Banking Relationships
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Wedbush Reiterates Bullish Stance on Relypsa (RLYP) Following Veltassa MoM Acceleration
April 18, 2016 11:47 AM EDTIn a note Friday, Wedbush analyst Liana Moussatos reiterated her Outperform rating and $52 price target on Relypsa, Inc. (NASDAQ: RLYP) after the third full month of Veltassa launch metrics shows month-over-month acceleration.
In March, 1,277 (+57% MoM) new patients started taking Veltassa with a free starter supply, 706 (+102% MoM) outpatient prescriptions were filled, and 201 (+14% MoM) hospital/institution units were sold.
Veltassa's early launch continues to track... More
BTIG Trims Q1 Sales Outlook on Relypsa's (RLYP) Veltassa Following Recent Update; Affirms at 'Buy'
April 15, 2016 2:44 PM EDTBTIG affirms Relypsa, Inc. (Nasdaq: RLYP) with a Buy rating and $45 price target after the company disclosed new patient starts, outpatient prescriptions and... More
Mizuho Weighs in on Relypsa (RLYP) Veltassa Numbers and Latest on M&A
April 15, 2016 9:59 AM EDTMizuho Securities analyst Irina Koffler weighed in on Relypsa, Inc. (NASDAQ: RLYP) following today's Veltassa prescriptions numbers and the latest M&A speculation.
Koffler noted that Veltassa prescriptions sold were in-line with their estimates. "Relypsa released March's Veltassa numbers, and reported 1,277 patients received a free starter supply of Veltassa, 706 retail prescriptions were filled, and 201 hospital packs were sold. In all, a total of 907 prescriptions/units were reimbursed. This compares to our estimates of 1,624 patients receiving the starter kit, 700 retail TRx's... More
